<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ertapenem: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ertapenem: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ertapenem: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11365" href="/d/html/11365.html" rel="external">see "Ertapenem: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12903" href="/d/html/12903.html" rel="external">see "Ertapenem: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F166533"><span class="drugH1">Brand Names: US</span>
<ul>
<li>INVanz</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866777"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>INVanz</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F166557"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Carbapenem</li></ul></div>
<div class="block doa drugH1Div" id="F166537"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Generally reserved for pathogens that are resistant to other antibiotics (eg, extended-spectrum beta-lactamase–producing organisms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Munoz-Price.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Munoz-Price.1'])">Ref</a></span>). Ertapenem lacks activity against <i>Pseudomonas aeruginosa</i> (unlike other carbapenems).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b74db564-f66e-4f55-8b58-9759dc214a0c">Bite wound infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, treatment (animal or human bite) (alternative agent) (off-label use):</b>
<b>IV:</b> 1 g once daily. Duration of treatment for established infection (which may include oral step-down therapy) is typically 5 to 14 days and varies based on patient-specific factors, including clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1','lexi-content-ref-Baddour.2','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1','lexi-content-ref-Baddour.2','lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (pathogen-directed therapy for susceptible gram-negative organisms) (off-label use):</b>
<b>IV:</b> 1 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>). Duration is 7 to 14 days, depending on source and extent of infection, as well as clinical response; a 7-day duration is recommended for patients with uncomplicated Enterobacteriaceae bacteremia who respond appropriately to antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.1','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.1','lexi-content-ref-30535100'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe:</b>
<b>IM, IV:</b> 1 g once daily. Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis but varies based on patient-specific factors, including clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9474c76-c81a-48ef-b80f-72ce1a0e25f5">Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients unable to take first-line agents (eg, piperacillin/tazobactam) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute:</i>
<b>IV:</b> 1 g once daily; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infections (eg, perforated appendix, appendiceal abscess, cholangitis, diverticulitis):</i>
<b>IM, IV:</b> 1 g once daily. Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c92ca38-0c20-4ec4-b5f0-113c6ccf7cd2">Osteomyelitis and/or discitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis and/or discitis (pathogen-directed therapy for susceptible gram-negative organisms) (off-label use): IV:</b> 1 g once daily, generally for ≥6 weeks depending on patient-specific factors, such as extent of infection, debridement, and clinical response. Shorter courses are appropriate if the affected bone is completely resected (eg, by amputation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-osmon.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-osmon.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fb013f00-067f-48b7-8802-317acc3d010f">Pelvic infections, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic infections, acute (eg, postpartum and postsurgical gynecologic infections) (alternative agent):</b>
<b>IM, IV:</b> 1 g once daily; duration of therapy varies based on type of infection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Community-acquired pneumonia, empiric therapy (inpatients without risk factors for </i>
<i>Pseudomonas aeruginosa</i>
<i>):</i> IM, IV:</b> 1 g once daily as part of an appropriate combination regimen. Duration (which may include oral step-down therapy) is for a minimum of 5 days; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.1','lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.1','lexi-content-ref-31573350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Hospital-acquired pneumonia or ventilator-associated pneumonia (pathogen-directed therapy for extended-spectrum beta-lactamase-producing organisms) (off-label use):</b></i>
<b>IV:</b> 1 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17540673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17540673'])">Ref</a></span>). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-klompas.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-klompas.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (pathogen-directed therapy for susceptible gram-negative organisms) (off-label use): IV:</b> 1 g every 24 hours; duration varies, but is generally 4 to 6 weeks for patients who undergo resection arthroplasty (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5389b037-d8ce-48e2-98b3-f8bb5a208a34">Skin and soft tissue infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For patients with select surgical site infections (intestinal, GU tract), necrotizing infections, or patients with or at risk for pathogens resistant to other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Stevens.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Stevens.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> 1 g once daily; often used as part of an appropriate combination regimen. Usual duration (including oral step-down therapy) is 5 to 14 days based on severity and clinical response; for necrotizing infections, continue until further debridement is not necessary and the patient has improved clinically and is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (colorectal surgery) (alternative agent):</b>
<b>IV:</b> 1 g within 60 minutes prior to surgical incision (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>). <b>Note:</b> Postoperative prophylaxis is not recommended in clean and clean-contaminated surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>). Some experts recommend against using ertapenem for surgical prophylaxis out of concern for inducing resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inpatients: </i>
<b>IV, IM:</b> 1 g once daily. Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1','lexi-content-ref-21292654','lexi-content-ref-15150185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1','lexi-content-ref-21292654','lexi-content-ref-15150185'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Outpatients:</i>
<b>IV, IM:</b> 1 g as a single dose, followed by 5 to 14 days of appropriate oral therapy.<b> Note: </b>For patients who are systemically ill, at risk for more severe illness, or at risk for multidrug-resistant infection, some experts continue daily parenteral therapy pending culture and susceptibility testing results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990673"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IM, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although the manufacturer’s labeling reports CrCl units as mL/minute/1.73 m<sup>2</sup>, it is not necessary to adjust CrCl estimates for BSA when dosing ertapenem, as renal clearance of a drug is proportional to an individual’s estimated CrCl in mL/minute, and ertapenem is generally well tolerated (Nix 2017; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: 500 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Daily dosing:</i>
<b>IM, IV: </b>500 mg once daily. When scheduled dose falls on a hemodialysis day, administer at least 6 hours prior to hemodialysis or wait until after hemodialysis; however, if the dose is given within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is required following hemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Three times weekly (post hemodialysis) dosing:</i>
<b>IM, IV:</b> 500 mg or 1 g 3 times weekly after hemodialysis on hemodialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24060141','lexi-content-ref-29992286','lexi-content-ref-31527026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24060141','lexi-content-ref-29992286','lexi-content-ref-31527026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Consider patient-specific factors such as body weight, infection severity, and residual kidney function when deciding between doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: IM, IV:</b> 500 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22083473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22083473'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations were developed through Monte Carlo simulation only and based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), organism minimum inhibitory concentration (MIC), and residual kidney function. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV: </b>1 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24323468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24323468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on daily treatments with 4 to 5 L/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26919659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26919659'])">Ref</a></span>) or 10 L/hour (Burkhardt 2009) of dialysate/ultrafiltrate flow rate for each 8- to 10-hour session. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), organism MIC, and residual kidney function. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV: </b>500 mg initially, then 500 mg post each PIRRT session or 1 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18723863','lexi-content-ref-26919659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18723863','lexi-content-ref-26919659'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987937"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Adjustments cannot be recommended (lack of experience and research in this patient population).</p></div>
<div class="block doe drugH1Div" id="F166538"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F166549"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12903" href="/d/html/12903.html" rel="external">see "Ertapenem: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Due to limited clinical data, ertapenem is usually reserved for extended-spectrum beta-lactamase infections with urinary sources or soft tissue infections when adequate source control has been achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24501388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24501388'])">Ref</a></span>). Ertapenem lacks activity against <i>Pseudomonas aeruginosa</i> (unlike other carbapenems).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: IM, IV: 15 mg/kg/dose twice daily; maximum dose: 500 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IM, IV: 1,000 mg once daily.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b>
<b>Note:</b> Guidelines recommend a treatment duration of 4 to 7 days (provided source controlled) for community-acquired, mild to moderate infections(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>); manufacturer labeling suggests a duration of 5 to 14 days; however, longer durations (&gt;7 days) have not been associated with improved outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children: IM, IV: 15 mg/kg/dose twice daily; maximum dose: 500 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IM, IV: 1,000 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fb013f00-067f-48b7-8802-317acc3d010f">Pelvic infections, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic infections, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children: IM, IV: 15 mg/kg/dose twice daily for 3 to 10 days based on severity of infection; maximum dose: 500 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IM, IV: 1,000 mg once daily for 3 to 10 days based on severity of infection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b>
<b>Note:</b> Guidelines suggest a usual duration of therapy of 10 days (including both parental and possible switch to appropriate oral step-down therapy); however, longer duration may be necessary for some organisms and/or complicated infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children: IM, IV: 15 mg/kg/dose twice daily for 10 to 14 days; maximum dose: 500 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IM, IV: 1,000 mg once daily for 10 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0baa4e1c-eea5-4294-8e1c-6a5d955a0d21">Skin and skin structure infection, complicated or necrotizing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection, complicated or necrotizing:</b>
<b>Note</b>: For complicated infection, continue therapy for 7 to 14 days. For necrotizing infection, use in combination with an agent effective against MRSA (eg, vancomycin, linezolid, daptomycin) for empiric therapy of polymicrobial (mixed) infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children: IM, IV: 15 mg/kg/dose twice daily; maximum dose: 500 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IM, IV: 1,000 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Limited data available: Children and Adolescents: IV: 15 mg/kg within 60 minutes prior to surgical incision; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (including pyelonephritis):</b>
<b>Note:</b> Duration includes possible switch to appropriate oral therapy after at least 3 days of parenteral treatment, once clinical improvement demonstrated.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children: IM, IV: 15 mg/kg/dose twice daily for 10 to 14 days; maximum dose: 500 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IM, IV: 1,000 mg once daily for 10 to 14 days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51128325"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;">There are no pediatric specific recommendations; based on experience in adult patients, dosage adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51108681"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not be adequately studied.</p></div>
<div class="block arsc drugH1Div" id="F58435972"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clostridioides difficile infection (CDI) has occurred with ertapenem, including <b>
<i>Clostridioides difficile</i>-associated diarrhea</b> (CDAD) and <b>
<i>Clostridioides difficile</i> colitis</b>. Ertapenem for surgical prophylaxis is associated with an increased incidence of hospital-onset CDI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17182989','lexi-content-ref-26278576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17182989','lexi-content-ref-26278576'])">Ref</a></span>). Ertapenem does not appear to have a higher risk of CDI compared to other carbapenems (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35708330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35708330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; potentially related to recent or cumulative antibiotic exposure. Ertapenem may cause disruption of the intestinal microbiota resulting in the overgrowth of pathogens, such as <i>C. difficile </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29689301','lexi-content-ref-29462280','lexi-content-ref-21653301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29689301','lexi-content-ref-29462280','lexi-content-ref-21653301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; often occurs between 5 and 30 days after initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23871314','lexi-content-ref-22146873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23871314','lexi-content-ref-22146873'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (carbapenems among highest risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other healthcare setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors, H<sub>2</sub> blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carbapenems, including ertapenem, may cause CNS toxicity. Noteworthy CNS effects caused by ertapenem include <b>encephalopathy</b>, <b>altered mental status</b>, <b>hallucinations</b>, and <b>seizures</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203577'])">Ref</a></span>). Ertapenem is associated with a lower seizure risk than other carbapenems, potentially due to structural differences at the C-2 position and/or unique pharmacokinetic properties, such as small volume of distribution and high protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7797443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7797443'])">Ref</a></span>). Resolution to baseline mental status after discontinuation often occurs within 2 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21177419','lexi-content-ref-25487647','lexi-content-ref-28203577','lexi-content-ref-22579271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21177419','lexi-content-ref-25487647','lexi-content-ref-28203577','lexi-content-ref-22579271'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not clearly established; postulated to be due to the antagonism of the GABA<sub>A</sub> receptor binding site. A carbapenem with a basic C-2 side chain increases the binding to GABA<sub>A </sub>(eg, imipenem) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7797443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7797443'])">Ref</a></span>). Ertapenem has an acidic carboxyl group at the C-2 position and is expected to have the lowest binding to GABA<sub>A</sub>, subsequently reducing its potential for neurotoxic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8383938','lexi-content-ref-28203577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8383938','lexi-content-ref-28203577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; signs of neurotoxicity are often observed within 5 to 7 days after the initial ertapenem dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21177419','lexi-content-ref-28203577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21177419','lexi-content-ref-28203577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting neurologic conditions (eg, brain injury, seizures, stroke) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21449629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21449629'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug accumulation in kidney impairment or hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32618479','lexi-content-ref-25487647','lexi-content-ref-21449629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32618479','lexi-content-ref-25487647','lexi-content-ref-21449629'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate (including <b>anaphylaxis</b> and<b> urticaria</b>) and delayed hypersensitivity reactions have been reported. Delayed hypersensitivity reactions range from <b>skin rash </b>to rare severe cutaneous adverse reactions (SCARs), including <b>acute generalized exanthematous pustulosis </b>(AGEP) and <b>drug reaction with eosinophilia and systemic symptoms </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23886234','lexi-content-ref-31398843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23886234','lexi-content-ref-31398843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are IgE-mediated. Delayed hypersensitivity reactions, including morbilliform drug eruptions (MDE) and SCARs, are generally mediated by T-cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-36740326','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-36740326','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Immediate hypersensitivity reactions: Rapid; IgE-mediated reactions (anaphylaxis, urticaria) generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; MDE typically occur ~7 to 10 days after initiation. Other delayed hypersensitivity reactions, including SCARs, typically occur days to 8 weeks after drug exposure, but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>). AGEP has been reported within 2 days after initiation of ertapenem (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23886234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23886234'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous hypersensitivity to carbapenems</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between penicillins/cephalosporins and carbapenems is considered ≤1% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27164625','lexi-content-ref-25457154','lexi-content-ref-24180646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27164625','lexi-content-ref-25457154','lexi-content-ref-24180646'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Despite similar core structures, cross-reactions between carbapenems have not been well described and several case reports of selective immediate or delayed reactions to a specific carbapenem with tolerance to another have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31398843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31398843'])">Ref</a></span>). Ertapenem has been tolerated in a patient following a hypersensitivity reaction to meropenem (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30763732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30763732'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F166502"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (infants, children, adolescents, adults: 9% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Asystole (&lt;2%), atrial fibrillation (&lt;2%), bradycardia (&lt;2%), cardiac arrhythmia (&lt;2%), chest pain (infants, children, adolescents, adults: &lt;2%), edema (≤3%), flushing (&lt;2%), heart failure (&lt;2%), heart murmur(&lt;2%), hypertension (&lt;2%), hypotension (1% to 2%), phlebitis (infants, children, adolescents, adults: &lt;2%), syncope (&lt;2%), tachycardia (&lt;2%), thrombophlebitis (&lt;2%), ventricular tachycardia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (infants, children, adolescents, adults: &lt;2%), desquamation (&lt;2%), diaphoresis (&lt;2%), erythema of skin (&lt;2%), erythematous rash (infants, children, and adolescents: &lt;2%), pruritus (infants, children, adolescents, adults: ≤2%), skin lesion (infants, children, and adolescents: &lt;2%), skin rash (infants, children, adolescents, adults: 2% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Skin Rash</span>, urticaria (&lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Ertapenem: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ertapenem)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ertapenem)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infants, children, and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg/kg twice daily up to a maximum of 1 g daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">384</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Ceftriaxone</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infants, children, and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg/kg twice daily up to maximum of 1 g daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">384</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">24</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Ticarcillin and Clavulanate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 g daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">802</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">774</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Piperacillin and Tazobactam</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 g daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">942</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Ceftriaxone</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (&lt;2%), decreased serum potassium (&lt;2%), dehydration (&lt;2%), increased serum glucose (&lt;2%), increased serum potassium (&lt;2%), increased serum sodium (&lt;2%), weight loss (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (&lt;2%), abdominal pain (infants, children, adolescents, adults: 4% to 5%), acid regurgitation (&lt;2%), anorexia (&lt;2%), cholelithiasis (&lt;2%), <i>Clostridioides difficile</i>-associated diarrhea (&lt;2%), constipation (infants, children, adolescents, adults: 2% to 4%), decreased appetite (infants, children, and adolescents: &lt;2%), duodenitis (&lt;2%), dysgeusia (&lt;2%), dyspepsia (&lt;2%), dysphagia (&lt;2%), esophagitis (&lt;2%), flatulence (&lt;2%), gastritis (&lt;2%), gastrointestinal hemorrhage (&lt;2%), hemorrhoids (&lt;2%), hiccups (&lt;2%), intestinal obstruction (&lt;2%), nausea (infants, children, adolescents: &lt;2%; adults: 6% to 9%), oral candidiasis (infants, children, adolescents, adults: &lt;2%), oral mucosa ulcer (&lt;2%), pancreatitis (&lt;2%), pyloric stenosis (&lt;2%), sore throat (&lt;2%), stomatitis (&lt;2%), upper abdominal pain (infants, children, and adolescents: &lt;2%), vomiting (infants, children, adolescents, adults: 4% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anuria (&lt;2%), bladder dysfunction (&lt;2%), finding of blood in urine (increased red blood cells: 1% to 3%), genital rash (infants, children, and adolescents: &lt;2%), hematuria (&lt;2%), oliguria (&lt;2%), proteinuria (infants, children, and adolescents: &lt;2%), urinary retention (&lt;2%), vaginitis (1% to 3%), vulvovaginal candidiasis (&lt;2%), vulvovaginal pruritus (&lt;2%), vulvovaginitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (3%), decreased hemoglobin (5%), decreased neutrophils (infants, children, adolescents: 6%; adults: &lt;2%), decreased platelet count (&lt;2%), decreased white blood cell count (infants, children, adolescents, adults: &lt;2%), eosinophilia (infants, children, adolescents, adults: ≤2%), hematoma (&lt;2%), leukocyturia (2% to 3%), prolonged partial thromboplastin time (&lt;2%), prolonged prothrombin time (&lt;2%), thrombocythemia (infants, children, adolescents: &lt;2%; adults: 4% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (infants, children, adolescents, adults: 4% to 9%), increased serum alkaline phosphatase (infants, children, adolescents: &lt;2%; adults: 4% to 7%), increased serum aspartate transaminase (infants, children, adolescents, adults: 4% to 8%), increased serum bilirubin (&lt;2%; including increased direct serum bilirubin or increased indirect serum bilirubin), jaundice (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (abdominal: infants, children, and adolescents: &lt;2%), candidiasis (infants, children, adolescents, adults: &lt;2%), herpes simplex infection (infants, children, and adolescents: &lt;2%), septic shock (&lt;2%), septicemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (infants, children, and adolescents: 4%), induration at injection site (infants, children, adolescents, adults: &lt;2%), infused vein complication (5% to 7%), infusion-site pain (infants, children, adolescents: 7%), injection-site phlebitis (infants, children, adolescents: &lt;2%), injection-site pruritus (infants, children, and adolescents: &lt;2%), pain at injection site (&lt;2%), swelling at injection site (infants, children, and adolescents: &lt;2%), warm sensation at injection site (infants, children, and adolescents: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (&lt;2%), altered mental status (3% to 5%; including agitation, confusion, decreased mental acuity, delirium, disorientation, drowsiness, stupor)<span class="lexi-table-link-container"> (<a aria-label="Altered Mental Status table link" class="lexi-table-link" data-table-id="lexi-content-altered-mental-status" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-altered-mental-status')">table 2</a>)</span><span class="table-link" style="display:none;">Altered Mental Status</span>, anxiety (&lt;2%), asthenia (&lt;2%), chills (&lt;2%), depression (&lt;2%), dizziness (infants, children, adolescents, adults: ≤2%), fatigue (&lt;2%), headache (infants, children, adolescents, adults: 4% to 7%), hypoesthesia (&lt;2%), hypothermia (infants, children, and adolescents: &lt;2%), insomnia (infants, children, adolescents, adults: ≤3%), malaise (&lt;2%), nervousness (&lt;2%), pain (&lt;2%), paresthesia (&lt;2%), subdural hematoma (&lt;2%), tremor (&lt;2%), vertigo (&lt;2%), voice disorder (&lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Altered Mental Status" frame="border" id="lexi-content-altered-mental-status" rules="all">
<caption style="text-align:center;">
<b>Ertapenem: Adverse Reaction: Altered Mental Status</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ertapenem)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ertapenem)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 g daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">802</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">774</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Piperacillin and Tazobactam</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 g daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">942</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Ceftriaxone</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (infants, children, and adolescents: &lt;2%), gout (&lt;2%), lower extremity pain (&lt;2%), muscle spasm (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Flank pain (&lt;2%), increased blood urea nitrogen (&lt;2%), increased serum creatinine (&lt;2%), renal insufficiency (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (&lt;2%), bronchoconstriction (&lt;2%), cough (infants, children, adolescents, adults: ≤4%), dyspnea (1% to 3%), epistaxis (&lt;2%), hemoptysis (&lt;2%), hypoxemia (&lt;2%), nasopharyngitis (infants, children, and adolescents: &lt;2%), pharyngitis (infants, children, adolescents, adults: &lt;2%; including viral), pleural effusion (infants, children, adolescents, adults: &lt;2%), pleuritic chest pain (&lt;2%), rales (&lt;2%), respiratory distress (&lt;2%), rhinitis (infants, children, and adolescents: &lt;2%), rhinorrhea (infants, children, and adolescents: &lt;2%), rhonchi (&lt;2%), upper respiratory tract infection (infants, children, and adolescents: 2%), wheezing (infants, children, and adolescents: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (infants, children, adolescents, adults: 2% to 5%), swelling (infants, children, adolescents, adults: ≤3%), tissue necrosis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Seizure<span class="lexi-table-link-container"> (<a aria-label="Seizure table link" class="lexi-table-link" data-table-id="lexi-content-seizure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-seizure')">table 3</a>)</span><span class="table-link" style="display:none;">Seizure</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Seizure" frame="border" id="lexi-content-seizure" rules="all">
<caption style="text-align:center;">
<b>Ertapenem: Adverse Reaction: Seizure</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ertapenem)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Piperacillin and Tazobactam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Ceftriaxone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ertapenem)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Piperacillin and Tazobactam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ceftriaxone)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 g daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,954</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">774</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">942</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Postmarking (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Fernando 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (Kennedy 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis (Itani 2006), staining of tooth</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, drug reaction with eosinophilia and systemic symptoms, hypersensitivity angiitis, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, ataxia, encephalopathy (Sutton 2017), hallucination (Sutton 2017), impaired consciousness, myasthenia, myoclonus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia</p></div>
<div class="block coi drugH1Div" id="F166515"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams; known hypersensitivity to local anesthetics of the amide type due to the use of lidocaine as a diluent (IM use only).</p></div>
<div class="block war drugH1Div" id="F166500"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate to severe renal dysfunction. Increased seizure risk has been reported in patients with renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Valproic acid and derivatives: Carbapenems, including ertapenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Lower doses (based upon renal function) are often required in the elderly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• IM administration: Doses for IM administration are mixed with lidocaine; consult Lidocaine (Systemic) information for associated Warnings/Precautions.</p></div>
<div class="block foc drugH1Div" id="F166510"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">INVanz: 1 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F166496"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323133"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ertapenem Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $48.00 - $166.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866778"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">INVanz: 1 g (3.2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea)</p></div>
<div class="block adm drugH1Div" id="F166512"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Avoid injection into a blood vessel. Make sure patient does not have an allergy to lidocaine or another anesthetic of the amide type. Administer by deep IM injection into a large muscle mass (eg, gluteal muscle or lateral part of the thigh). Do not administer IM preparation or drug reconstituted for IM administration intravenously.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an IV infusion over 30 minutes. May also administer IV push over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29992286','lexi-content-ref-23400916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29992286','lexi-content-ref-23400916'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612718"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer by deep IM injection into a large muscle mass such as the gluteus maximus or lateral part of the thigh. Avoid injection into a blood vessel. Must be administered within 1 hour of reconstitution.</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV infusion: Infuse over 30 minutes; administration should be completed within 6 hours of reconstitution. Do not coinfuse with other medications. <b>Do not infuse with dextrose-containing solutions.</b></p></div>
<div class="block use drugH1Div" id="F166511"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure: </b>For the treatment of complicated intra-abdominal infections caused by <i>Clostridium clostridioforme</i>, <i>Escherichia coli, </i>
<i>Eubacterium lentum</i>, <i>Peptostreptococcus</i> spp, <i>Bacteroides distasonis</i>, <i>Bacteroides fragilis</i>, <i>Bacteroides ovatus</i>, <i>Bacteroides thetaiotaomicron</i>, or <i>Bacteroides uniformis</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic infection:</b> For the treatment of acute pelvic infections, including postpartum endomyometritis, septic abortion, and postsurgical gynecologic infections caused by <i>Streptococcus agalactiae</i>, <i>E. coli</i>, <i>B. fragilis</i>, <i>Porphyromonas asaccharolytica</i>, <i>Peptostreptococcus</i> spp, or <i>Prevotella bivia</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community acquired:</b> For the treatment of community-acquired pneumonia (CAP) caused by <i>Streptococcus pneumoniae</i> (penicillin-susceptible isolates only), including cases with concurrent bacteremia; <i>Haemophilus influenzae</i> (beta-lactamase-negative isolates only); or <i>Moraxella catarrhalis</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection, complicated:</b> For the treatment of complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis caused by <i>Staphylococcus aureus</i> (methicillin-susceptible isolates only), <i>S. agalactiae</i>, <i>Streptococcus pyogenes</i>, <i>E. coli</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, <i>B. fragilis</i>, <i>Peptostreptococcus</i> spp, <i>P. asaccharolytica</i>, or <i>P. bivia</i>. Ertapenem has not been studied in diabetic foot infections with concomitant osteomyelitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> For the prophylaxis of surgical site infection in adults following elective colorectal surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b> For the treatment of complicated urinary tract infection, including pyelonephritis caused by <i>E. coli</i>, including cases with concurrent bacteremia or <i>K. pneumoniae</i>.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Methicillin-resistant <i>Staphylococcus aureus, Enterococcus</i> spp, <i>Acinetobacter</i>, <i>Pseudomonas aeruginosa</i>, and penicillin-resistant strains of <i>Streptococcus pneumoniae </i>are <b>resistant</b> to ertapenem while most extended-spectrum beta-lactamase (ESBL)-producing bacteria remain sensitive to ertapenem.</p></div>
<div class="block off-label drugH1Div" id="F25473714"><span class="drugH1">Use: Off-Label: Adult</span><p>Bite wound, treatment (animal or human bite); Bloodstream infection; Osteomyelitis and/or discitis; Pneumonia, hospital acquired or ventilator associated; Prosthetic joint infection</p></div>
<div class="block mst drugH1Div" id="F166564"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ertapenem may be confused with doripenem, imipenem, meropenem</p>
<p style="text-indent:-2em;margin-left:4em;">Invanz may be confused with IV vancomycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Invanz [US, Canada, Qatar] may be confused with Avinza [Puerto Rico] and Evista brand name for raloxifene [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299280"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F166504"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Ertapenem.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Ertapenem may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F166516"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Ertapenem is approved for the treatment of postpartum endomyometritis, septic abortion, and postsurgical infections. Ertapenem may be considered for use as an alternative antibiotic in the treatment of intraamniotic infection (ACOG 712 2017).</p></div>
<div class="block brc drugH1Div" id="F166517"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ertapenem is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of ertapenem is &lt;1% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 1 g/day.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of ertapenem was calculated using a milk concentration of 0.38 mcg/mL, providing an estimated daily infant dose via breast milk of 57 mcg/kg/day. This milk concentration was obtained following maternal administration ertapenem 1 g IV to five lactating women at 5 to14 days postpartum. Milk concentrations were measured randomly for 5 days following the last dose. The milk concentration within 24 hours of the last dose ranged from &lt;0.13 mcg/mL (lower limit of quantitation) to 0.38 mcg/mL. Peak concentrations were not assessed. Ertapenem was not detectable in the milk of four women and was less than the lower limit of quantitation in one woman by day 5 after the last dose.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F166518"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F166508"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic renal, hepatic, and hematopoietic assessment during prolonged therapy; neurological assessment</p></div>
<div class="block pha drugH1Div" id="F166499"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F166514"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Almost complete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children: ~0.2 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents 13 to 17 years: ~0.16 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~0.12 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding (concentration dependent, primarily to albumin): 85% at 300 mcg/mL, 95% at &lt;100 mcg/mL</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Non-CYP-mediated hydrolysis to inactive metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: IM: ~90%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children: ~2.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents and Adults: ~4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: IM: ~2.3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~80% as unchanged drug and metabolite); feces (~10%)</p></div>
<div class="block phksp drugH1Div" id="F51154053"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Unbound AUC increased 1.5- and 2.3-fold in those with mild and moderate renal function impairment, respectively. Unbound AUC increased 4.4- and 7.6-fold in those with advanced renal impairment and end-stage renal disease, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The total and unbound AUC increased 37% and 67%, respectively, in elderly patients relative to younger patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC).</p>
<p style="text-indent:-2em;margin-left:8em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:10em;">Gram-negative organisms (<i>E. coli</i>, <i>K. pneumoniae</i>): Goal: ≥40% <i>f</i>T &gt; MIC (bactericidal) (DeRyke 2011).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>S. pneumoniae</i>: Goal: ≥30% <i>f</i>T &gt; MIC (bactericidal) (Xuan 2002).</p>
<p style="text-indent:-2em;margin-left:8em;">Population specific:</p>
<p style="text-indent:-2em;margin-left:10em;">Critically ill patients in the ICU: Minimum goal: ≥50% <i>f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% <i>f</i>T &gt; 4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">C<sub>max </sub>(peak): Single dose:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and children 3 to 23 months of age: IV: 15 mg/kg (maximum dose: 1 g): 103.8 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to 12 years of age: IV: 15 mg/kg (maximum dose: 1 g): 113.2 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents 13 to 17 years of age: IV: 1 g: 155.9 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Adults:</p>
<p style="text-indent:-2em;margin-left:12em;">IV: 1 g: 155 mg/L.</p>
<p style="text-indent:-2em;margin-left:12em;">IM: 1 g: 67 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Minimal bacterial killing continues after ertapenem concentration falls below the MIC of targeted pathogen and varies based on the organism:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>S. aureus</i>: ~1.5 hours (Odenholt 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>S. pneumoniae</i>: ~2.4 hours (Odenholt 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-negative organisms (<i>Enterobacter cloacae</i>, <i>E. coli</i>, <i>H. influenzae</i>): ≤0.7 hours (Odenholt 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869380"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Wandara</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ertapenem</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ertiga</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ertapenem bergamo | Ertapenem imedic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Invanz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Iverzam</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and sepsis working group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910809">
<a name="32910809"></a>Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. <i>J Antimicrob Chemother.</i> 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/32910809/pubmed" id="32910809" target="_blank">32910809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742677">
<a name="28742677"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 712: intrapartum management of intraamniotic infection. <i>Obstet Gynecol</i>. 2017;130(2):e95-e101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/28742677/pubmed" id="28742677" target="_blank">28742677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anderson.1">
<a name="Anderson.1"></a>Anderson DJ, Sexton DJ. Antimicrobial prophylaxis for prevention of surgical site infection in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18945594">
<a name="18945594"></a>Arguedas A, Cespedes J, Botet FA, et al. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. <i>Int J Antimicrob Agents</i>. 2009;33(2):163-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/18945594/pubmed" id="18945594" target="_blank">18945594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour LM. Soft tissue infections due to dog and cat bites. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 25, 2019a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2">
<a name="Baddour.2"></a>Baddour LM. Soft tissue infections due to human bites. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 25, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.1">
<a name="Barshak.1"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17540673">
<a name="17540673"></a>Bassetti M, Righi E, Fasce R, et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. <i>J Antimicrob Chemother</i>. 2007;60(2):433-435. doi: 10.1093/jac/dkm180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/17540673/pubmed" id="17540673" target="_blank">17540673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017 [published correction appears in <i>JAMA Surg</i>. 2017;152(8):803]. <i>JAMA Surg</i>. 2017;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;53(7):e25-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283. doi: 10.2146/ajhp120568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27164625">
<a name="27164625"></a>Buonomo A, Pascolini L, Rizzi A, et al. Cross-reactivity and tolerability of ertapenem in patients with IgE-mediated hypersensitivity to β-lactams. <i>J Investig Allergol Clin Immunol</i>. 2016;26(2):100-105. doi:10.18176/jiaci.0019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/27164625/pubmed" id="27164625" target="_blank">27164625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18723863">
<a name="18723863"></a>Burkhardt O, Hafer C, Langhoff A, et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. <i>Nephrol Dial Transplant</i>. 2009;24(1):267-271. doi: 10.1093/ndt/gfn472.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/18723863/pubmed" id="18723863" target="_blank">18723863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22083473">
<a name="22083473"></a>Cardone KE, Grabe DW, Kulawy RW, et al. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.<i> Antimicrob Agents Chemother</i>. 2012;56(2):725-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/22083473/pubmed" id="22083473" target="_blank">22083473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22290982">
<a name="22290982"></a>Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. <i>Antimicrob Agents Chemother</i>. 2012;56(4):2173-2177. doi: 10.1128/AAC.05913-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/22290982/pubmed" id="22290982" target="_blank">22290982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29689301">
<a name="29689301"></a>Connelly S, Subramanian P, Hasan NA, Colwell RR, Kaleko M. Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome. <i>Anaerobe</i>. 2018;53:82-93. doi:10.1016/j.anaerobe.2018.04.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/29689301/pubmed" id="29689301" target="_blank">29689301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12921489">
<a name="12921489"></a>Curran M, Simpson D, Perry C. Ertapenem: A Review of Its Use in the Management of Bacterial Infections. <i>Drugs.</i> 2003;63(17):1855-1878.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/12921489/pubmed" id="12921489" target="_blank">12921489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17283197">
<a name="17283197"></a>DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. <i>Antimicrob Agents Chemother</i>. 2007;51(4):1481-1486. doi:10.1128/AAC.00752-06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/17283197/pubmed" id="17283197" target="_blank">17283197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21177419">
<a name="21177419"></a>Duquaine S, Kitchell E, Tate T, Tannen RC, Wickremasinghe IM. Central nervous system toxicity associated with ertapenem use. <i>Ann Pharmacother</i>. 2011;45(1):e6. doi:10.1345/aph.1P528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/21177419/pubmed" id="21177419" target="_blank">21177419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32618479">
<a name="32618479"></a>El Nekidy WS, Elrefaei H, St John TJL, et al. Ertapenem neurotoxicity in hemodialysis patients-safe and effective dosing is still needed: a retrospective study and literature review. <i>Ann Pharmacother</i>. 2021;55(1):52-58. doi:10.1177/1060028020938059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/32618479/pubmed" id="32618479" target="_blank">32618479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24323468">
<a name="24323468"></a>Eyler RF, Vilay AM, Nader AM, et al. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. <i>Antimicrob Agents Chemother</i>. 2014;58(3):1320-1326. doi: 10.1128/AAC.02090-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/24323468/pubmed" id="24323468" target="_blank">24323468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>FAQs for clinicians about <i>C. diff</i>. Centers for Disease Control and Prevention. Updated October 25, 2022. Accessed July 19, 2023. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23886234">
<a name="23886234"></a>Fernando SL. Ertapenem-induced acute generalized exanthematous pustulosis with cross-reactivity to other beta-lactam antibiotics on patch testing. <i>Ann Allergy Asthma Immunol</i>. 2013;111(2):139-140. doi:10.1016/j.anai.2013.05.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/23886234/pubmed" id="23886234" target="_blank">23886234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25457154">
<a name="25457154"></a>Gaeta F, Valluzzi RL, Alonzi C, Maggioletti M, Caruso C, Romano A. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins. <i>J Allergy Clin Immunol</i>. 2015;135(4):972-976. doi:10.1016/j.jaci.2014.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/25457154/pubmed" id="25457154" target="_blank">25457154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24060141">
<a name="24060141"></a>Geerlings CJ, de Man P, Rietveld AP, Touw DJ, Cohen Tervaert JW. A practical thrice weekly ertapenem dosage regime for chronic hemodialysis patients? <i>Clin Nephrol</i>. 2013;80(4):312. doi: 10.5414/cn108071.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/24060141/pubmed" id="24060141" target="_blank">24060141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36740326">
<a name="36740326"></a>Gibson A, Deshpande P, Campbell CN, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. <i>J Allergy Clin Immunol</i>. 2023;151(2):289-300.e4. doi:10.1016/j.jaci.2022.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/36740326/pubmed" id="36740326" target="_blank">36740326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30763732">
<a name="30763732"></a>Gil-Serrano J, Cardona V, Luengo O, et al. Anaphylactic shock to meropenem with ertapenem tolerance: a case report. <i>J Allergy Clin Immunol Pract</i>. 2019;7(6):2057-2058. doi:10.1016/j.jaip.2019.01.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/30763732/pubmed" id="30763732" target="_blank">30763732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090866">
<a name="29090866"></a>Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci</i>. 2018;25(1):3-16. doi: 10.1002/jhbp.518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/29090866/pubmed" id="29090866" target="_blank">29090866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22047594">
<a name="22047594"></a>Goswami ND, Johnson MD, Chu VH. Ertapenem for treatment of osteomyelitis: a case series.<i> BMC Res Notes</i>. 2011;4:478. doi: 10.1186/1756-0500-4-478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/22047594/pubmed" id="22047594" target="_blank">22047594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care.</i> 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.1">
<a name="Hooton.1"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26907184">
<a name="26907184"></a>Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, et al; REIPI/ESGBIS/INCREMENT Group. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>J Antimicrob Chemother</i>. 2016;71(6):1672-1680. doi: 10.1093/jac/dkv502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/26907184/pubmed" id="26907184" target="_blank">26907184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23871314">
<a name="23871314"></a>Hansen D, Pollan LD, Fernando H. Fulminant <i>Clostridium difficile</i> colitis: a complication of perioperative antibiotic prophylaxis. <i>J Oral Maxillofac Surg</i>. 2013;71(11):1880-1885. doi:10.1016/j.joms.2013.04.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/23871314/pubmed" id="23871314" target="_blank">23871314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8383938">
<a name="8383938"></a>Hikida M, Masukawa Y, Nishiki K, Inomata N. Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. <i>Antimicrob Agents Chemother</i>. 1993;37(2):199-202. doi:10.1128/AAC.37.2.199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/8383938/pubmed" id="8383938" target="_blank">8383938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29992286">
<a name="29992286"></a>Hsaiky LM, Salinitri FD, Wong J, et al. Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. <i>Nephrol Dial Transplant</i>. 2019;34(10):1766-1772. doi: 10.1093/ndt/gfy166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/29992286/pubmed" id="29992286" target="_blank">29992286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24501388">
<a name="24501388"></a>Hsu AJ, Tamma PD. Treatment of multidrug-resistant gram-negative infections in children. <i>Clin Infect Dis</i>. 2014;58(10):1439-1448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/24501388/pubmed" id="24501388" target="_blank">24501388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invanz.1">
<a name="Invanz.1"></a>Invanz (ertapenem) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invanz.3">
<a name="Invanz.3"></a>Invanz (ertapenem) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17182989">
<a name="17182989"></a>Itani KM, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. <i>N Engl J Med</i>. 2006;355(25):2640-2651. doi:10.1056/NEJMoa054408<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/17182989/pubmed" id="17182989" target="_blank">17182989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16225376">
<a name="16225376"></a>Keating GM and Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. <i>Drugs.</i> 2005;65(15):2151-2178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/16225376/pubmed" id="16225376" target="_blank">16225376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31863282">
<a name="31863282"></a>Kennedy KE, Teng C, Patek TM, Frei CR. Hypoglycemia associated with antibiotics alone and in combination with sulfonylureas and meglitinides: an epidemiologic surveillance study of the FDA Adverse Event Reporting System (FAERS) [published online December 20, 2019]. <i>Drug Saf</i>. 2019;10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/31863282/pubmed" id="31863282" target="_blank">31863282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-klompas.2019">
<a name="klompas.2019"></a>Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25487647">
<a name="25487647"></a>Lee KH, Ueng YF, Wu CW, Chou YC, Ng YY, Yang WC. The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews. <i>J Clin Pharm Ther</i>. 2015a;40(2):240-244. doi:10.1111/jcpt.12239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/25487647/pubmed" id="25487647" target="_blank">25487647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26278576">
<a name="26278576"></a>Lee S, Prasad P, Lin M, Garritson S, Nichols A, Liu C. Ertapenem prophylaxis associated with an increased risk of <i>Clostridium difficile</i> infection among surgical patients. <i>Infect Control Hosp Epidemiol</i>. 2015b;36(11):1351-1354. doi:10.1017/ice.2015.193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/26278576/pubmed" id="26278576" target="_blank">26278576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31398843">
<a name="31398843"></a>Lee Y, Bradley N. Overview and insights into carbapenem allergy. <i>Pharmacy (Basel)</i>. 2019;7(3):110. doi:10.3390/pharmacy7030110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/31398843/pubmed" id="31398843" target="_blank">31398843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26919659">
<a name="26919659"></a>Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy.<i> J Clin Pharmacol</i>. 2016;56(10):1277-1287. doi: 10.1002/jcph.727.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/26919659/pubmed" id="26919659" target="_blank">26919659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis</i>. 2012;54(12):e132-e173. doi: 10.1093/cid/cis346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection.<i> Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi: 10.1089/sur.2016.261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>. 2010;50(7):1079. <i>Clin Infect Dis</i>. 2010;50(3):457]. <i>Clin Infect Dis.</i> 2009;49(1):1-45. doi: 10.1086/599376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21449629">
<a name="21449629"></a>Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. <i>Pharmacotherapy</i>. 2011;31(4):408-423. doi:10.1592/phco.31.4.408<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/21449629/pubmed" id="21449629" target="_blank">21449629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.1">
<a name="Moehring.1"></a>Moehring R, Anderson DV. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 25, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Munoz-Price.1">
<a name="Munoz-Price.1"></a>Munoz-Price LS. Extended-spectrum beta-lactamases. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed July 19, 2023. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15150180">
<a name="15150180"></a>Nix DE, Majumdar AK, and DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. <i>J Antimicrob Chemother.</i> 2004;53(suppl 2):ii23-ii28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/15150180/pubmed" id="15150180" target="_blank">15150180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28947625">
<a name="28947625"></a>Nix DE, Mayersohn M, Erstad BL. Should estimates of glomerular filtration rate and creatinine clearance be indexed to body surface area for drug dosing? <i>Am J Health Syst Pharm</i>. 2017;74(21):1814-1819. doi:10.2146/ajhp160467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/28947625/pubmed" id="28947625" target="_blank">28947625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9736564">
<a name="9736564"></a>Odenholt I, Löwdin E, Cars O. In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria. <i>Antimicrob Agents Chemother</i>. 1998;42(9):2365-2370. doi:10.1128/AAC.42.9.2365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/9736564/pubmed" id="9736564" target="_blank">9736564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-osmon.2019">
<a name="osmon.2019"></a>Osmon DR, Tande AJ. Osteomyelitis in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2013;56(1):e1-e25. doi: 10.1093/cid/cis803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35708330">
<a name="35708330"></a>Park JJ, Jung EJ, Kim JY, Seo YB, Lee J, Jung Y. Thirty-day mortality rates in patients with extended-spectrum β-lactamase-producing <i>Enterobacterales</i> bacteremia receiving ertapenem versus other carbapenems. <i>Antimicrob Agents Chemother</i>. 2022;66(7):e0028722. doi:10.1128/aac.00287-22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/35708330/pubmed" id="35708330" target="_blank">35708330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.1">
<a name="Pemberton.1"></a>Pemberton JH. Acute colonic diverticulitis: Medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?<i> Clin Infect Dis</i>. 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24180646">
<a name="24180646"></a>Romano A, Gaeta F, Valluzzi RL, et al. Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins. <i>Allergy</i>. 2013;68(12):1618-1621. doi:10.1111/all.12299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/24180646/pubmed" id="24180646" target="_blank">24180646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>. 2010;50(12):1695]. <i>Clin Infect Dis</i>. 2010;50(2):133-164. doi: 10.1086/649554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stevens.1">
<a name="Stevens.1"></a>Stevens DL, Baddour LM. Necrotizing soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21653301">
<a name="21653301"></a>Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of <i>Clostridium difficile</i> infection. <i>Clin Infect Dis</i>. 2011;53(1):42-48. doi:10.1093/cid/cir301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/21653301/pubmed" id="21653301" target="_blank">21653301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7797443">
<a name="7797443"></a>Sunagawa M, Matsumura H, Sumita Y, Nouda H. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. <i>J Antibiot (Tokyo)</i>. 1995;48(5):408-416. doi:10.7164/antibiotics.48.408<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/7797443/pubmed" id="7797443" target="_blank">7797443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203577">
<a name="28203577"></a>Sutton SS, Jumper M, Cook S, Edun B, Wyatt MD. Ertapenem-induced encephalopathy in a patient with normal renal function. <i>J Investig Med High Impact Case Rep</i>. 2017;5(1):2324709616689376. doi:10.1177/2324709616689376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/28203577/pubmed" id="28203577" target="_blank">28203577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31527026">
<a name="31527026"></a>Ueng YF, Wang HJ, Wu SC, Ng YY. A practical thrice weekly ertapenem in hemodialysis patients. <i>Antimicrob Agents Chemother</i>. 2019;63(12):e01427-19. doi:10.1128/AAC.01427-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/31527026/pubmed" id="31527026" target="_blank">31527026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.1">
<a name="Vollmer.1"></a>Vollmer CM Jr, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15150185">
<a name="15150185"></a>Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. <i>J Antimicrob Chemother</i>. 2004;53(suppl 2):ii67-ii74. doi:10.1093/jac/dkh208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/15150185/pubmed" id="15150185" target="_blank">15150185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.1">
<a name="Weintrob.1"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22579271">
<a name="22579271"></a>Wen MJ, Sung CC, Chau T, Lin SH. Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure. <i>Clin Nephrol</i>. 2013;80(6):474-478. doi:10.5414/CN107247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/22579271/pubmed" id="22579271" target="_blank">22579271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23400916">
<a name="23400916"></a>Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. <i>Pharmacotherapy</i>. 2013;33(3):266-274. doi: 10.1002/phar.1197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/23400916/pubmed" id="23400916" target="_blank">23400916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference">
                  Xuan D, Banevicius M, Capitano B, Kim MK, Nightingale C, Nicolau D. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. <i>Antimicrob Agents Chemother.</i> 2002;46(9):2990-2995. doi:10.1128/aac.46.9.2990-2995.2002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/12183258/pubmed" id="12183258" target="_blank">12183258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a non-inferiority randomized controlled trial [published online December 11, 2018]. <i>Clin Infect Dis.</i> doi: 10.1093/cid/ciy1054.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8675 Version 337.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
